ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
- 13 May 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (543)
- https://doi.org/10.1126/scitranslmed.aaz5660
Abstract
Human genetics, biomarker, and animal studies implicate loss of function in bone morphogenetic protein (BMP) signaling and maladaptive transforming growth factor–β (TGFβ) signaling as drivers of pulmonary arterial hypertension (PAH). Although sharing common receptors and effectors with BMP/TGFβ, the function of activin and growth and differentiation factor (GDF) ligands in PAH are less well defined. Increased expression of GDF8, GDF11, and activin A was detected in lung lesions from humans with PAH and experimental rodent models of pulmonary hypertension (PH). ACTRIIA-Fc, a potent GDF8/11 and activin ligand trap, was used to test the roles of these ligands in animal and cellular models of PH. By blocking GDF8/11- and activin-mediated SMAD2/3 activation in vascular cells, ACTRIIA-Fc attenuated proliferation of pulmonary arterial smooth muscle cells and pulmonary microvascular endothelial cells. In several experimental models of PH, prophylactic administration of ACTRIIA-Fc markedly improved hemodynamics, right ventricular (RV) hypertrophy, RV function, and arteriolar remodeling. When administered after the establishment of hemodynamically severe PH in a vasculoproliferative model, ACTRIIA-Fc was more effective than vasodilator in attenuating PH and arteriolar remodeling. Potent antiremodeling effects of ACTRIIA-Fc were associated with inhibition of SMAD2/3 activation and downstream transcriptional activity, inhibition of proliferation, and enhancement of apoptosis in the vascular wall. ACTRIIA-Fc reveals an unexpectedly prominent role of GDF8, GDF11, and activin as drivers of pulmonary vascular disease and represents a therapeutic strategy for restoring the balance between SMAD1/5/9 and SMAD2/3 signaling in PAH.Keywords
Funding Information
- National Institutes of Health (5R01AR057374)
- National Institutes of Health (5R01HL131910)
- National Institutes of Health (5R42HL132742)
This publication has 47 references indexed in Scilit:
- Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal womenThe Journal of Clinical Pharmacology, 2013
- Human Primary Lung Endothelial Cells in CultureAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Soluble activin receptor type IIB increases forward pulling tension in the mdx mouseMuscle & Nerve, 2011
- Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial CellsOnline Journal of Public Health Informatics, 2009
- Redundancy of myostatin and growth/differentiation factor 11 functionBMC Developmental Biology, 2009
- Activin-Like Kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by MonocrotalineThe American Journal of Pathology, 2009
- A soluble activin Type IIA receptor induces bone formation and improves skeletal integrityProceedings of the National Academy of Sciences of the United States of America, 2008
- Role of the TGF-β/Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for BMP-mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle CellsOnline Journal of Public Health Informatics, 2008
- Differential effects of TGF-β1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004